DIAGNOSTIC VALUE OF SERUM MMP-9 AND GRANZYME B IN BULLOUS PEMPHIGOID: A CASE–CONTROL STUDY
Nội dung chính của bài viết
Tóm tắt
Background: Bullous pemphigoid (BP) is a common autoimmune blistering disease in the elderly. Proteases like matrix metalloproteinase-9 (MMP-9) and granzyme B contribute to dermal–epidermal separation, but their circulating levels and clinical relevance remain unclear. Objectives: To compare serum levels of MMP-9 and granzyme B in BP patients versus healthy controls, and evaluate their correlations with disease severity and clinical features. Methods: This single-center case–control study in Hanoi, Vietnam (June 2024–June 2025) included 17 newly diagnosed BP patients and 17 age-matched healthy controls. Serum MMP-9 and granzyme B were measured by ELISA and normalized to total protein. Clinical parameters including BPDAI scores were recorded. Associations and diagnostic value were assessed using correlation and ROC analysis. Results: Serum MMP-9 levels were significantly lower in BP than controls (median 375.2 vs. 728.1 pg/µg protein; p = 0.0376), while granzyme B levels were higher but not statistically significant (p = 0.454). MMP-9 positively correlated with BPDAI (r = 0.47, p = 0.03), unlike granzyme B. MMP-9 and granzyme B showed moderate correlation (r = 0.66, p = 0.002). BP patients with diabetes had higher levels of both markers. Combining MMP-9 and granzyme B improved diagnostic accuracy (AUC = 0.844). Conclusions: Circulating MMP-9 levels are reduced in BP patients but correlate with disease severity. Granzyme B alone has limited value. Combined measurement enhances diagnostic performance and may aid in disease monitoring.
Chi tiết bài viết
Từ khóa
bullous pemphigoid; MMP-9; granzyme B; serum biomarkers; proteases.
Tài liệu tham khảo
2. Gleave A, Granville DJ. Granzyme B in Autoimmune Skin Disease. Biomolecules. 2023;13(2):388. DOI: 10.3390/biom13020388.
3. Hiroyasu S, Zeglinski MR, Zhao H, et al. Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. Nat Commun. 2021;12(1):302. DOI: 10.1038/s41467-020-20604-3.
4. Liu Z, Li N, Diaz LA, et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest. 2005;115(4):879–87. DOI: 10.1172/JCI23977.
5. Niimi Y, Pawankar R, Kawana S. Increased expression of MMP-2, MMP-9 and MMP-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol. 2006;139(2):104–13. DOI: 10.1159/000090385.
6. Masmoudi W, Vaillant M, Vassileva S, et al. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol. Jun 2021;184(6):1106-1112.
7. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32. DOI: 10.1016/S0140-6736(12)61140-4.
8. Velotti F, Barchetta I, Cimini FA, Cavallo MG. Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. Front Immunol. 2020;11:587581. DOI: 10.3389/fimmu.2020.587581